Top

Published in:

Open Access 01-07-2009 | Original Article

Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy

Authors: Nicolas Tsavaris, Andreas Lazaris, Christos Kosmas, Panagiotis Gouveris, Nikolaos Kavantzas, Petros Kopterides, Thomas Papathomas, George Arapogiannis, Haralambos Zorzos, Vassiliki Kyriakou, Efstathios Patsouris

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2009

Abstract

Purpose

Human DNA topoisomerases I and II (topo-I and -II) are essential for vital cellular processes such as DNA replication, transcription, translation, recombination, and repair. In the present study, we correlate topo-I and -II expression and outcome after chemotherapy in primary and relapsed colorectal cancer.

Patients and methods

Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study. All had undergone surgical resection of the primary tumor and received post-operatively 5-FU-based (5FU + Leucovorin, Mayo Clinic regimen) adjuvant chemotherapy. Tumor tissue was collected at the initial operation from the primary tumor and at the time of recurrence (during the second operation following chemotherapy). All tissue samples were analyzed for levels of expression of both topo-I and topo-IIa using standard three-step immunohistochemistry on paraffin sections.

Results

Forty patients were included. Levels of expression of topo-I and topo-II were higher in malignant cells from tumor recurrences compared to primary tumors (P = 0.0001 for both). There was a statistically significant positive relationship between patients age and levels of topo-I (P = 0.011) and topo-II (P = 0.011) expression.

Conclusions

The study results reported here underscore the role of topoisomerase expression in colorectal cancer and suggest a potential role in tumor recurrence.

Gupta M, Fujimori A, Pommier Y (1995) Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1262:1–14PubMed

Pommier Y, Pourquier P, Fan Y, Strumberg D (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400:83–105PubMed

Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279:1534–1541PubMedCrossRef

Merino A, Madden KR, Lane WS, Champoux JJ, Reinberg D (1993) DNA topoisomerase I is involved in both repression and activation of transcription. Nature 365:227–232PubMedCrossRef

Florell SR, Martinchick JF, Holden JA (1996) Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin’s lymphoma. Anticancer Res 16:3467–3474PubMed

Burden DA, Osheroff N (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1400:139–154PubMed

Kellner U, Jacobsen A, Kellner A, Mantke R, Roessner A, Röcken C (2003) Comparative genomic hybridization. Synchronous occurrence of focal nodular hyperplasia and hepatocellular carcinoma in the same liver is not based on common chromosomal aberrations. Am J Clin Pathol 119:265–271PubMedCrossRef

Nakopoulou L, Zervas A, Lazaris AC, Constantinides C, Stravodimos C, Davaris P, Dimopoulos C (2001) Predictive value of topoisomerase IIα immunostaining in urothelial bladder carcinoma. J Clin Pathol 54:309–313PubMedCrossRef

Gibbons D, Fogt F, Kasznica J, Holden J, Nikulasson S (1997) Comparison of topoisomerase II alpha and Ki-67 expression in uterine cervical squamous lesions. Mod Pathol 10:409–413PubMed

10.

Heck MM, Hittelman WN, Earnshaw WC (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85:1086–1090PubMedCrossRef

11.

Bronstein IB, Vorobyev S, Timofeev A, Jolles CJ, Alder SL, Holden JA (1996) Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res 8:17–25PubMed

12.

Holden JA, Rahn MP, Jolles CJ, Vorobyev SV, Bronstein IB (1997) Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinoma. J Clin Pathol 50:247–253CrossRef

13.

Boonsong A, Curran S, McKay JA, Cassidy J, Murray GI, McLeod HL (2002) Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol 33:1114–1119PubMedCrossRef

14.

Staley BE, Samowitz WS, Bronstein IB, Holden JA (1999) Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Mod Pathol 12:356–361PubMed

15.

Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A, Montemurro S, Giuliani F, Maiello E, Colucci G (2004) Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 111:252–258PubMedCrossRef

16.

Coleman LW, Perkins SL, Bronstein IB, Holden JA (2000) Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas. Hum Pathol 31:728–733PubMedCrossRef

17.

Monnin KA, Bronstein IB, Gaffney DK, Holden JA (1999) Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum Pathol 4:384–391CrossRef

18.

Gupta D, Bronstein IB, Holden JA (2000) Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival. Hum Pathol 31:214–219PubMedCrossRef

19.

Perego P, Capranico G, Supino R, Zunino F (1994) Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs 5:645–649PubMedCrossRef

20.

Coleman LW, Bronstein IB, Holden JA (2001) Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas. Anticancer Res 21:1167–1172PubMed

21.

Coleman LW, Rohr LR, Bronstein IB, Holden JA (2002) Human DNA topoisomerase I: an anticancer drug target present in human sarcomas. Hum Pathol 33:599–607PubMedCrossRef

22.

Lynch BJ, Bronstein IB, Holden JA (2001) Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J 7:176–180PubMedCrossRef

23.

Hafian H, Venteo L, Sukhanova A, Nabiev I, Lefevre B, Pluot M (2004) Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas. Hum Pathol 35:745–751PubMedCrossRef

24.

Shamaa AA, Zyada MM, Wagner MM, Awad SS, Osman MM, Abdel Azeem AA (2008) The significance of Epstein Barr Virus (EBV) & DNA topoisomerase IIu (DNA–TopoII) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC). Diagn Pathol 3:45 [Epub ahead of print]PubMedCrossRef

25.

Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J (1957) Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 179:663–666PubMedCrossRef

26.

Libutti SK, Salz LB, Rustgi AK, Tepper JE (2005) Cancer of the colon. In: Devita VT, Hellman S, Rosenberg S (eds) Cancer: principles and practice of oncology, Chap 29, Sect 8. Lippincott Williams and Wilkins, Philadelphia

27.

Gouveris P, Lazaris AC, Papathomas TG, Nonni A, Kyriakou V, Delladetsima J, Patsouris ES, Tsavaris N (2007) Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy. J Cancer Res Clin Oncol 133:1011–1015PubMedCrossRef

28.

Lazaris AC, Kavantzas NG, Zorzos HS, Tsavaris NV, Davaris PS (2002) Markers of drug resistance in relapsing colon cancer. J Cancer Res Clin Oncol 128:114–118PubMedCrossRef

29.

Zorzos HS, Lazaris AC, Korkolopoulou PA, Kavantzas NG, Tseleni-Balafouta S, Patsouris ES, Tsavaris NV, Davaris PS (2003) Multidrug resistance proteins and topoisomerase II alpha expression in colon cancer: association with metastatic potential. Pathology 35:315–318PubMedCrossRef

30.

Tsavaris N, Kosmas C, Zorzos H, Lazaris A, Vadiaka M, Dimitrakopoulos A, Siakantaris MP, Rokana S, Papalambros E, Pangalis GA, Davaris P (2004) Breast cancer after curative chemotherapy in non-Hodgkin’s lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer. Oncol Rep 11:899–903PubMed

31.

Ichikawa W, Uetake H, Nihei Z, Mastuo K, Fujita H, Yamada Y (1999) Topoisomerase I (Topo-I) expression correlates to thymidylate synthase (TS) expression in colorectal cancer (CRC). Proc Am Soc Clin Oncol 18:946 (abstract)

32.

Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223–3229PubMed

33.

Hande KR (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1400:173–184PubMed

34.

Luzzio MJ, Besterman JM, Emerson DL, Evans MG, Lackey K, Leitner PL, McIntyre G, Morton B, Myers PL, Peel M, Sisco JM, Sternbach DD et al (1995) Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem 38:395–401PubMedCrossRef

35.

Bleiberg H (1998) Continuing the fight against advanced colorectal cancer: new and future treatment options. Anticancer Drugs 9:18–28PubMedCrossRef

36.

Wilstermann AM, Bender RP, Godfrey M, Choi S, Anklin C, Berkowitz DB, Osheroff N, Graves DE (2007) Topoisomerase II-drug interaction domains: identification of substituents on etoposide that interact with the enzyme. Biochemistry 46:8217–8225PubMedCrossRef

37.

Bognel C, Rekacewicz C, Mankarios H, Pignon JP, Elias D, Duvillard P, Prade M, Ducreux M, Kac J, Rougier P, Eschwège F, Lasser P (1995) Prognostic value of neural invasion in rectal carcinoma: a multivariate analysis on 339 patients with curative resection. Eur J Cancer 31A:894–898PubMedCrossRef

38.

Rothenberg ML, Burris HA III (1994) Irinotecan as second line therapy for patients with 5-FU refractory colorectal cancer. Proc Am Soc Clin Oncol 13:198 (abstr)

39.

Conti JA, Saltz L (1994) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 13:195 (abstr)

40.

Pitot HC, O’Connell MJ (1994) A phase II trial of CPT-11 in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group Study. Proc Am Soc Clin Oncol 13:197 (abstr)

41.

Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723–3725PubMed

42.

Tsavaris N, Kosmas C, Skopelitis H, Papadoniou N, Polyzos A, Zografos G, Adoniou E, Gryniatsos J, Felekouras E, Zacharakis M, Sigala F, Bacoyiannis C et al (2007) Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study. Chemotherapy 53:282–291PubMedCrossRef

43.

Gennatas C, Papaxoinis G, Michalaki V, Mouratidou D, Andreadis C, Tsavaris N, Pafiti A (2006) A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma. J Chemother 18:538–544PubMed

44.

Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M, Dimitrakopoulos A, Karadima D, Rokana S, Papalambros E, Papastratis G, Margaris H et al (2003) Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. Cancer Chemother Pharmacol 52:514–519PubMedCrossRef

45.

Tsavaris NB, Polyzos A, Gennatas K, Kosmas Ch, Vadiaka M, Dimitrakopoulos A, Macheras A, Papastratis G, Tsipras H, Margaris H, Papalambros E, Giannopoulos A et al (2002) Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination. Chemotherapy 48:94–99PubMedCrossRef

46.

Mitry E, Ducreux M, Rougier P (1998) Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials. Bull Cancer 38-42

47.

Van Cutsem E, Peeters M (1998) Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials. Bull Cancer 33-7

48.

Boige V, Raymond E, Armand JP (1998) Irinotecan: various administration schedules, study of drug combinations, phase I experience. Bull Cancer 26-32

49.

Planting AS, van der Burg ME, van den Bent MJ, de Boer-Dennert M, Stoter G, Verweij J (1996) Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer. Br J Cancer 73:1265–1267PubMed

50.

Passalacqua R, Bisagni G, Cocconi G, Boni C, Di Blasio B, Ceci G (1991) Cisplatin and etoposide in advanced colorectal carcinoma. Ann Oncol 2:687–688PubMed

51.

Posner M, Slapak CA, Browne MJ, Clark JW, Curt G, Weitberg A, Calabresi P, Cummings FJ, Wiemann M, Urba S (1990) A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal cancer. Am J Clin Oncol 13:455–458PubMedCrossRef

52.

Colucci G, Maiello E, Giuliani F, Cifarelli RA, Giotta F (1995) Carboplatin and etoposide in previously treated colorectal cancer patients. Tumori 81:36–38PubMed

53.

Zelkowitz RS, Posner MR, Cummings F, Beitz J, Weitberg AB (1989) A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma. Am J Clin Oncol 12:492–493CrossRef

54.

Inaba M, Mitsuhashi J, Kawada S, Nakano H (1994) Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Jpn J Cancer Res 85:187–193PubMed

55.

Stuart K, Posner M, Campbell K, Huberman M (1995) Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma. Am J Clin Oncol 18:300–302PubMedCrossRef

56.

Tsavaris N, Kosmas C, Gennatas K, Vadiaka M, Skopelitis E, Xila V, Rokana S, Margaris E, Zografos G, Papastratis G, Kouraklis G (2002) Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU + LV pre-treated patients with advanced colorectal cancer. J Chemother 14:406–411PubMed

57.

Tsavaris N, Kosmas C, Gennatas K, Vadiaka M, Paliaros P, Dimitrakopoulos A, Diamantis T, Tsipras H, Papastratis G (2002) Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer. Med Sci Monit 8:65–69

Title: Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
Authors: Nicolas Tsavaris
Andreas Lazaris
Christos Kosmas
Panagiotis Gouveris
Nikolaos Kavantzas
Petros Kopterides
Thomas Papathomas
George Arapogiannis
Haralambos Zorzos
Vassiliki Kyriakou
Efstathios Patsouris
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0886-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2009

Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies

Anthocyanins-based drugs for colon cancer treatment: the nutritionist’s point of view

Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes

A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer

Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer